Introduction {#s1}
============

Vascular demarcations in the eye are both striking and vital for vision. The completely avascular photoreceptor layer of the retina lies between the vascular inner retina (on its apical aspect) and the highly vascularized and permeable fenestrated choriocapillaris ([@bib11]) (on its basal aspect) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The choroid, which has the highest flow of any vascular bed ([@bib10]), fulfills the metabolic and oxygen demands of the retinal pigmental epithelium (RPE) cells and photoreceptors. In age-related macular degeneration (AMD), angiogenic vessels from the inner retina extend into the photoreceptors (retinal angiomatous proliferation, or RAP), or from choroidal vessels breaching through the complex of the RPE and Bruch's membrane (BrM) into the subretinal space (choroidal neovascularization, CNV). Either can disrupt retinal structure and function, causing irreversible vision loss ([@bib4]). Although AMD is the leading cause of irreversible blindness in the West ([@bib4]), its etiology has not been fully elucidated.

Understanding the molecular underpinnings of the physiological vascular zoning ability of the retina has been a challenge for retinal biology for decades and may provide a better understanding of AMD pathogenesis. Vascular endothelial growth factor A (VEGF-A) is a potent angiogenic factor with a crucial role in both normal and pathologic vascular growth within the eye ([@bib47]; [@bib48]; [@bib45]; [@bib12]; [@bib44]), and its increased expression is linked to pathologic proliferation of abnormal, highly permeable vessels into the avascular photoreceptor layers ([@bib7]; [@bib4]; [@bib45]). A soluble isoform of VEGF receptor-1 (sVEGFR-1, also known as sFLT-1) acts as a naturally occurring inhibitor of VEGF-A-mediated angiogenesis ([@bib29]). sFLT-1 negatively regulates VEGF-A action: first, it binds and sequesters VEGF-A; and second, by heterodimerizing with membrane-bound VEGF-receptor-2, it prevents VEGF-A occupancy and subsequent signal transduction ([@bib30]). Excess levels of sFLT-1 strongly inhibit CNV in mice and monkeys ([@bib34]; [@bib38]). In addition, we previously demonstrated that endogenous sFLT-1 is both necessary and sufficient for corneal avascularity ([@bib5]). Therefore, we hypothesized that avascular photoreceptor privilege depends on sFLT-1 and that a deficiency of endogenous sFLT-1 might be involved in CNV or RAP development.

Results {#s2}
=======

sFLT-1 is decreased in AMD RPE and photoreceptors {#s2-1}
-------------------------------------------------

Although the specificity of soluble FLT-1 antibody had been verified, we further confirmed this by ELISA as it is crucial to distinguish it from membrane FLT-1 ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). We then compared sFLT-1 expression in healthy human eyes and eyes with AMD or RAP (patient information is shown in [Table 1](#tbl1){ref-type="table"}) by two different immunostaining methods. Both results demonstrated that soluble FLT-1 was strikingly decreased in the RPE and photoreceptor layers in all AMD (n = 3) and RAP eyes (n = 3) compared with age matched controls, respectively ([Figure 1A](#fig1){ref-type="fig"}, [Figure 2---figure supplement 3](#fig1s3){ref-type="fig"}); conversely, as has been previously reported, VEGF-A was upregulated significantly in the retina of AMD eyes ([@bib4]).10.7554/eLife.00324.003Table 1.Demographic information for human globes**DOI:** [http://dx.doi.org/10.7554/eLife.00324.003](10.7554/eLife.00324.003)NormalNormalNormalNormalNormalAMD (CNV)AMD (dry)AMDRAPRAPRAP25/M71/M79/F80/F89/F80/F86/F88/F67/M86/F86/F[^2][^3]10.7554/eLife.00324.004Figure 1.Soluble FLT-1 expression is reduced in the photoreceptors and RPE from AMD eyes.(**A**) Representative immunostaining images show soluble FLT-1 expression was significantly decreased in an age-related macular degeneration (AMD) eye with choroidal neovascularization (CNV) (top, 80 years old, female) and retinal angiomatous proliferation (RAP) (bottom, 67 years old, female) compared with aged-matched controls (80 years old and 71 years old, respectively, females; black arrow heads point to the photoreceptors; red arrows point to the CNV or RAP lesions). (**B**) In situ hybridizations show the localization of *sFlt-1* (purple/blue) in the photoreceptors and retinal pigment epithelium (RPE) layers in Balb/c mice. (**C**) Immunohistochemistry (IHC) staining shows sFLT-1 and VEGF expression in wild type mice. Higher relative expression of sFLT-1 to VEGF is observed in the photoreceptors. The magnified images (bottom) from the framed area showed that soluble FLT-1 is expressed in the basal side of the RPE layer. (**D**) Representative IHC image shows sFLT-1 is expressed in the basal side of the RPE layer in a young adult healthy human eye (25 years old, male). CC: choriocapillaris; IN: inner nuclear layer; IS: inner segment layer; ON: outer nuclear layer; OS: outer segment layer. Arrows point to the RPE layer. Scale bar: 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.004](10.7554/eLife.00324.004)10.7554/eLife.00324.005Figure 1---figure supplement 1.Avascularity of the outer retina (photoreceptors and RPE and BrM) surrounded by the inner retina with abundant vessels and the highly vascularized choroid in a normal human eye.Red: perlecan staining of vessels; blue: DAPI. Arrow heads point to the vessels. BrM: Bruch\'s membrane; Ch: choroid; RPE: retinal pigment epithelium; CC: choriocapillaris.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.005](10.7554/eLife.00324.005)10.7554/eLife.00324.006Figure 1---figure supplement 2.sFLT-1 antibody specifically binds to the unique motif of sFLT-1.Results correspond to an ELISA in which wells are coated with: BLANK, 1% BSA; FLT/FC, a chimeric protein containing the extracellular region of FLT-1 and the human Fc fragment (R&D Systems, Minneapolis, MN); SF, the peptide utilized to immunize the rabbits to obtain sFLT-1 antibody (the peptide corresponding to a fragment of the unique C-terminal tail of sFLT-1).**DOI:** [http://dx.doi.org/10.7554/eLife.00324.006](10.7554/eLife.00324.006)10.7554/eLife.00324.007Figure 1---figure supplement 3.sFLT-1 expression is significantly decreased in RPE from an AMD eye with CNV (88 years old, female) compared with the age-matched control (89 years old, female).The right bottom bright field images shows autofluorescence from degenerated RPE (green fluorescence blocks the dark pigment of RPE overlying CNV; arrows point to CNV). AMD: age-related macular degeneration; Br: Bruch\'s membrane; Ch: choroid; CNV: choroidal neovascularization; RPE: retinal pigment epithelium.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.007](10.7554/eLife.00324.007)10.7554/eLife.00324.008Figure 1---figure supplement 4.H&E staining images show the histology of two human RAP eyes (arrows point to the RAP lesion).Ch: choroid; RAP: retinal angiomatous proliferation; RPE: retinal pigment epithelium; Ph: Photoreceptor layer.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.008](10.7554/eLife.00324.008)

Photoreceptors and RPE synthesize and express sFLT-1 {#s2-2}
----------------------------------------------------

We next assessed sFLT-1 expression in the retina. In situ hybridization and immunostaining confirmed the presence of sFLT-1 mRNA and protein, respectively, in photoreceptors and RPE, which indicated that both cell types can synthesize and express sFLT-1 ([Figure 1B,C](#fig1){ref-type="fig"}). Compared with VEGF-A ([Figure 1C](#fig1){ref-type="fig"}), the relative expression pattern of soluble FLT-1 to VEGF is higher in the photoreceptors than in the inner vascular layers of the retina. A theoretical implication is that VEGF is prominent in the inner vascularized retina, the layer which harbors blood vessels and neurons, while sFLT-1 is prominent in the outer avascular retina, consistent with our initial hypothesis. Furthermore, sFLT-1 was principally detected on the basal aspect of the RPE--BrM complex, facing the vascularized choroid ([Figure 1C,D](#fig1){ref-type="fig"}). In contrast, in the RPE, VEGF-A localizes on both basal and apical surfaces, consistent with a prior report ([@bib11]). This polarized distribution is reminiscent of sFLT-1 expression in the cornea, where the highest levels of sFLT-1 are found in the perilimbal region counterposing the vascularized conjunctiva ([@bib6]). This is consistent with VEGF's vasculotrophic role in the choroid and neurotrophic role in the photoreceptors ([@bib47]). The different ratio and polarities of VEGF-A and sFLT-1 would likely strike a reasonable balance to maintain a healthy photoreceptor layer and choriocapillaris while preventing vascular invasion of the subretinal space.

Anti-FLT-1 antibodies induce CNV {#s2-3}
--------------------------------

Given the localization and expression patterns of sFLT-1, we sought to determine if suppression of subretinal sFLT-1 in mice would induce subretinal angiogenesis or CNV. First, we injected a neutralizing antibody against FLT-1 into the subretinal space in wild type mice. This resulted in increased free VEGF-A levels (n = 10; p*\<*0.005) and induced CNV (n = 10, p*\<*0.00005; [Figure 2A,B](#fig2){ref-type="fig"}), suggesting that sequestration of VEGF-A by FLT-1 maintains subretinal avascularity. Next, we administered FLT-1 neutralizing antibody (which occupies domains 1--4 of this receptor) via subretinal injection in *Flt-1 tk*^*−/−*^ mice, which are deficient in the tyrosine kinase domain of membrane-bound FLT-1 ([@bib21]). The results demonstrated that the induced CNV in *Flt-1 tk*^*−/−*^ mice was accompanied with higher VEGF levels (n = 10; p*\<*0.005; [Figure 2C,D](#fig2){ref-type="fig"}), strongly suggesting that CNV occurs due to disruption of sFLT-1, but not of mFLT-1 activity (which is inactive in these mice). This accords with prior studies which have found that soluble but not membrane-bound FLT-1 plays a key role in anti-angiogenic regulation, based on the finding that germline *Flt-1* deletion leads to embryonic lethality due to vascular endothelial hyperplasia, while membrane-bound *Flt-1* lacking the tyrosine kinase domain is sufficient for normal vascular development in mice ([@bib16]; [@bib28]).10.7554/eLife.00324.009Figure 2.Suppression of sFLT-1 by neutralizing antibodies induces CNV while elevating levels of VEGF.VEGF-A levels were tested by ELISA of retinal pigment epithelium (RPE)/choroid tissue lysates harvested immediately after CNV images were taken in vivo. (**A** and **C**) Subretinal injections of FLT-1 antibody induced CNV and increased VEGF-A levels in both wild type and *Flt-1 tk*^*−/−*^ mice. (**B** and **D**) Representative FA (at a phase of 3 min after fluorescein injection) and OCT images. Arrows point to CNV. (**E**) ELISA for PlGF showed no significant difference 3 days after subretinal injections of FLT-1 neutralizing antibody and isotype control. CNV: choroidal neovascularization; FA: fluorescein angiography; OCT: optical coherence tomography.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.009](10.7554/eLife.00324.009)10.7554/eLife.00324.010Figure 2---figure supplement 1.Goat anti-mouse FLT-1 neutralizing antibody does not affect ELISA assessment of mouse VEGF-A and mouse PlGF-2.Goat anti-mouse FLT-1 neutralizing antibody or control goat IgG was added to the standard at 1 ng/ml. (**A**) Mouse VEGF-A ELISA. (**B**) Mouse PlGF-2 ELISA. p Values were calculated by paired Student t test (each average was paired). The presence of anti-FLT-1 antibody did not significantly affect ELISA readings of either cytokine.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.010](10.7554/eLife.00324.010)10.7554/eLife.00324.011Figure 2---figure supplement 2.Excess recombinant FLT-1 inhibits VEGF-A and PlGF-2 detection.Recombinant FLT-1 was added to each concentration of VEGF-A (**A**) or PlGF-2 (**B**) and abolished detection of VEGF-A and PlGF-2 over background levels, indicating that VEGF-A or PlGF-2 that is bound to FLT-1 is not detected by this assay.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.011](10.7554/eLife.00324.011)10.7554/eLife.00324.012Figure 2---figure supplement 3.FLT-1 neutralizing antibody incubation resulted in release of VEGF-A from recombinant FLT-1 in vitro.The design schema is shown on the left. A 2 mg/ml sample of mouse FLT-1-Fc protein (471-F1; R&D Systems, Minneapolis, MN) was immobilized on an ELISA plate. After blocking with 1% BSA, the plate was incubated in 2 ng/ml mouse VEGF-A (493-MV-005; R&D) or mouse PlGF-2 (465-PL-010; R&D) at room temperature (RT) for 2 hr. Then, each well was incubated in (**A**) 2 ng/ml mouse VEGF-A, (**B**) 2 ng/ml mouse VEGF-A + 5 mg/ml isotype IgG, (**C**) 2 ng/ml mouse VEGF-A + 5 mg/ml anti-FLT-1 IgG (AF471; R&D), (**D**) 2 ng/ml mouse PlGF-2, (**E**) 2 ng/ml mouse PlGF-2 + 5 mg/ml isotype IgG, or (**F**) 2 ng/ml mouse PlGF-2 + 5 mg/ml anti-FLT-1 IgG at RT for 6 hr. Using biotinylated anti-VEGF-A (BAF493; R&D) or biotinylated anti-PlGF-2 (BAF465; R&D) and streptavidin-HRP (DY998; R&D), VEGF-A or PlGF-2 was detected. The results (row **C** vs row **F**) show that FLT-1 neutralizing antibody desequestered VEGF-A but not PlGF-2 from FLT-1. \*p\<0.0001 by two-tailed Student t test.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.012](10.7554/eLife.00324.012)

In addition to VEGF-A, sFLT-1 also binds VEGF-B and placental growth factor (PlGF) ([@bib40]; [@bib15]). To determine if PlGF is essential for CNV, we performed subretinal injections of anti-FLT-1 and isotype control antibody in wild type mice and found no significant difference in PlGF expression between both groups at day 3 (n = 9; [Figure 2E](#fig2){ref-type="fig"}) or at day 10 (undetectable levels). Taken together with the above finding that FLT-1 antibody induced CNV in *Flt-1 tk*^*−/−*^ mice (in which VEGF-B signaling would be expected to be inoperative), this indicates that CNV induced by FLT-1 blockade is mediated by desequestration of VEGF-A, not of PlGF or VEGF-B. Moreover, neither PlGF nor VEGF-B are able to compensate for VEGF-A during its blockade, and mice lacking either factor display only minor developmental defects ([@bib40]; [@bib57]). Furthermore, it is well established that, in contrast to VEGF-A, VEGF-B is neither induced by hypoxia nor essential to angiogenesis ([@bib22]; [@bib57]). Although VEGF-B is dispensable for blood vessel growth, it is critical for blood vessel survival in pathological conditions ([@bib57]). However, our findings do not exclude a role for VEGF-B in RAP or CNV. Knocking down sFLT-1 could increase VEGF-B activity and promote the longevity of CNV lesions after formation rather than promote angiogenesis. However, this pro-survival function is mediated through membrane-bound FLT-1.

Considering the high affinity sFLT-1 has for VEGF, it is crucial to verify that blocking antibodies can displace VEGF from bound sFLT-1 and release free VEGF. Moreover, anti-VEGF antibodies may affect the quantification of VEGF and PlGF, and another consideration is that the particular ELISA used may measure 'non-free' VEGF or PlGF (bound to sFLT-1) as well. To clarify these questions, we performed the following series of experiments. First, we determined whether the neutralizing anti-FLT-l antibody affected the measurement of mouse VEGF-A and PlGF-2, the only isoform of this protein present in mice by ELISA ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We did not find any significant difference.

Next, to determine whether our ELISA would detect VEGF that is bound to FLT-1, we examined the effect of excess recombinant FLT-1 protein on the detection of VEGF-A and PlGF-2 by ELISA ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). In this assay, almost all VEGF-A (62.5 pg/ml) would be expected to bind FLT-1 (100 ng/ml) based on an assumed Kd = 10 pM (free VEGF-A can be estimated to be 1.36 pg/ml by Michaelis--Menten kinetics). The ELISA showed less detection of VEGF-A and PlGF after saturation with excess recombinant FLT-1, that is, it did not detect non-free VEGF-A and non-free PlGF-2. These data demonstrate that non-free VEGF or non-free PlGF-2 is not being detected at significant levels by our ELISA technique.

Finally, we determined whether anti-FLT-1 neutralizing antibody released VEGF-A but not PlGF-2 from recombinant FLT-1 ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). After coating ELISA plates with FLT-1 and then incubating with VEGF-A or PlGF-2, Flt-1 neutralizing antibody was added. The results demonstrate that FLT-1 neutralizing antibody released VEGF-A but not PlGF-2 from recombinant FLT-1. Although the exact reason for this is unknown, it is possible that FLT-1 neutralizing antibody may change the FLT-1 conformation, affecting binding of FLT-1 to VEGF-A but not PlGF-2.

AAV.shRNA.*sFlt-1* induces CNV {#s2-4}
------------------------------

Our second strategy was a post-transcriptional selective knockdown of sFLT-1 via subretinal injection of adeno-associated viral (AAV) delivery of a short hairpin RNA (shRNA) targeting sFLT-1 (AAV.shRNA.*sFlt-1.Gfp*). We have previously shown that this shRNA is selective to sFLT-1 and does not affect membrane-bound FLT-1 ([@bib5]). We further confirmed this by western blot ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). As controls, shRNA (AAV.shRNA.*Gfp*), viral vector expressing non-specific cargo (AAV.*Gfp*), or phosphate buffered saline (PBS) was injected into the subretinal space. Subretinal delivery of AAV.shRNA.*sFlt-1.Gfp* demonstrated efficient transduction of the RPE and the photoreceptor layer ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). We analyzed CNV and measured VEGF-A at 4 weeks after subretinal injection instead of 10 days as above, as AAV-mediated subretinal gene delivery usually takes a longer time before expression ([@bib53]). Compared to controls, treatment with AAV.shRNA.*sFlt-1*.*Gfp* resulted in downregulation of sFLT-1 ([Figure 3A](#fig3){ref-type="fig"}), increased free VEGF-A (n = 10; p*\<*0.05; [Figure 3B](#fig3){ref-type="fig"}), and induced CNV (n = 10; p*\<*0.05; [Figure 3B,C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Furthermore, as we reported recently ([@bib39]), AAV.shRNA.*sFlt-1* induced primary CNV (defined as a CNV that initially occurred at the injection site), as well as secondary CNV (defined as a lesion that is more than ½ a disc diameter from the primary CNV lesion, and that shows no leakage on fluorescein angiography (FA) at least 2 weeks after injection) 4 weeks after injection. This phenomenon was not found in the controls, although insignificant CNV developed initially due to injury. The length of time required for secondary CNV occurrence might derive from the time to and long duration of AAV-mediated gene expression in the mouse eye which has previously been demonstrated ([@bib49]; [@bib31]; [@bib53]). To further determine if CNV induced by sFLT-1 inhibition is attributable to VEGF-A, we repeated the above set of AAV-mediated sFLT-1 knockdown studies in *Vegfa*^*lox/lox*^ mice ([@bib18]). The reduction of VEGF protein in RPE cells via subretinal delivery of a plasmid encoding Cre recombinase (pCre) in *Vegfa*^*loxp/loxp*^ mice was demonstrated by immunohistochemistry (IHC) staining ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). Cre expression was verified by western blot ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}). Increased VEGF-A expression in the RPE/choroid (n = 10; p*\<*0.0005) and CNV (n = 10; p*\<*0.05) in *Vegfa*^*lox/lox*^ mice treated with subretinal AAV.shRNA.*sFlt-1* ([Figure 3D](#fig3){ref-type="fig"}) was suppressed by subretinal delivery of pCre. This confirms that the release of sequestered VEGF-A is requisite for CNV development following sFLT-1 antagonism. We observed that the sFLT-1 fluorescence signal became stronger after subretinal injection in treatment or control ([Figure 3A](#fig3){ref-type="fig"}) eyes compared to normal eyes without injury ([Figure 1C](#fig1){ref-type="fig"}). The higher sFLT-1 expression might be due to the inflammatory reaction following injury.10.7554/eLife.00324.013Figure 3.Subretinal adeno-associated viral delivery of short hairpin RNA targeting sFLT-1 induces VEGF-A and CNV.VEGF-A levels from retinal pigment epithelium (RPE)/choroid tissues were tested by ELISA from tissue lysates harvested immediately after choroidal neovascularization (CNV) images were taken in vivo. (**A**) Western blot (top) and immunohistochemistry (IHC) staining of sFLT-1 results confirmed that sFLT-1 was knocked down by AAV.shRNA.*sFlt-1.Gfp* but not in controls at 4 weeks. (**B**) Subretinal AAV.shRNA.*sFlt-1*.*Gfp* induced CNV and VEGF-A compared to controls in wild type mice (4 weeks). CNV was observed in controls due to disruption of Bruch's membrane by subretinal injection. (**C**) Representative fluorescein angiography (FA) and H&E staining images (40×) (arrows point to leakage or neovessels) show CNV is more extensive after AAV.shRNA.*sFlt-1*.*Gfp* treatment compared to controls. (**D**) CNV was not induced by subretinal AAV.shRNA.*sFlt-1* when VEGF-A release was suppressed (4 weeks) by pCre in *Vegfa*^*lox/lox*^ mice compared with pNull control in which VEGF levels rose and CNV was induced. (**E**) IFN-γ levels increased in AAV.shRNA.*sFlt-1*.*Gfp* and AAV.shRNA.*Gfp* (4 weeks) compared with AAV.*Gfp* and phosphate buffered saline (PBS) in C57BL/6J mice. No significant difference was found among groups in the *Tlr3*^*−/−*^ mice (4 weeks). (**F**) Subretinal AAV.shRNA.*sFlt-1*.*Gfp* induced VEGF-A and CNV (4 weeks) in *Tlr3*^*−/−*^ mice. Representative FA images show the leakage in each group. VEGF-A levels were tested by ELISA using RPE/choroid complex samples. \*p*\<*0.05; \*\*p*\<*0.005; \*\*\*p*\<*0.0005. NS: no significant difference. Scale bar: 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.013](10.7554/eLife.00324.013)10.7554/eLife.00324.014Figure 3---figure supplement 1.Western blot shows that AAV.shRNA.*sFlt-1.Gfp* specifically affects sFLT-1 but not mFLT-1.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.014](10.7554/eLife.00324.014)10.7554/eLife.00324.015Figure 3---figure supplement 2.AAV.shRNA.*sFlt-1.Gfp* (A) transfected more than 3 out of 4 quadrants and targeted the photoreceptors, RPE, and BrM by subretinal injection (2 weeks). (B) Sham control.The fundi are imaged by a Spectralis imager in vivo (top). Retinal cross-sections (bottom) are imaged by confocal microscopy. Green is GFP, blue is DAPI. Scale bar: 10 µm. BrM: Bruch\'s membrane; GFP: green fluorescent protein; IN: inner nuclear layer; ON: outer nuclear layer; Ph: photoreceptors; RPE: retinal pigment epithelium.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.015](10.7554/eLife.00324.015)10.7554/eLife.00324.016Figure 3---figure supplement 3.Representative images show different sizes of CNV in AAV.shRNA.*sFlt-1.Gfp* (A) and controls (B) at 4 weeks after subretinal injection.FA and ICG images were taken in vivo. Representative immunohistochemistry staining on flat-mounts (4×) and cryosections (20×) and transmission electron microscopy images showed abundant neovessels (arrows) in AAV.shRNA.*sFlt-1.Gfp* but not control injection. Scale bar: 10 μm. CNV: choroidal neovascularization; FA: fluorescein angiography; ICG: indocyanine green.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.016](10.7554/eLife.00324.016)10.7554/eLife.00324.017Figure 3---figure supplement 4.IHC staining of VEGF indicates that the VEGF decreased in the area of injection (arrows) but not in the non-injected area (arrow heads).Top: VEGF; middle: VEGF + bright field; bottom: isotype control of VEGF. Scale bar: 10 µm. IHC: immunohistochemistry; RPE: retinal pigment epithelium.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.017](10.7554/eLife.00324.017)10.7554/eLife.00324.018Figure 3---figure supplement 5.Western blot confirms Cre expression in *Vegfa*^lox/lox^ mice 10 days after pCre subretinal delivery (lane 1: pCre, lane 2: pNull).**DOI:** [http://dx.doi.org/10.7554/eLife.00324.018](10.7554/eLife.00324.018)10.7554/eLife.00324.019Figure 3---figure supplement 6.IL-12 levels increased in both AAV.shRNA.*sFlt-1.Gfp* and AAV.shRNA.*Gfp* treated mice (4 weeks) compared to AAV.Gfp and PBS control in the C57BL/6J mice.No significant difference was found between each group of *Tlr3*^*−/−*^ mice (4 weeks).**DOI:** [http://dx.doi.org/10.7554/eLife.00324.019](10.7554/eLife.00324.019)

Treatment with siRNAs can affect several cytokines, such as interferon-gamma (IFN-γ) and interleukin 12 (IL-12), via activation of toll-like receptor 3 (TLR3), and suppress CNV as a general siRNA class effect ([@bib33]). We found that AAV.shRNA, targeting either *sFlt-1* or a non-specific sequence, up-regulated IFN-γ (n = 10; p*\<*0.01) and IL-12 (n = 10; p*\<*0.001; [Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}), both of which are induced by TLR3. However, non-specific AAV.shRNA.*Gfp* failed to induce CNV in wild type mice (n = 10; [Figure 3B](#fig3){ref-type="fig"}), suggesting that CNV formation in AAV.shRNA.*sFlt-1*.*Gfp* treated mice is due not to non-specific immune activation but rather to sFLT-1 suppression. To confirm this, we repeated the described experiments in Tlr3-knockout mice (*Tlr3*^--/--^ mice). Subretinal injection of AAV.shRNA*.sFlt-1*.*Gfp* (n = 10) but not non-specific AAV.shRNA.*Gfp* (n = 10) increased VEGF-A levels (p*\<*0.05) and induced CNV (p*\<*0.005) in *Tlr3*^--/--^ mice ([Figure 3F](#fig3){ref-type="fig"}). Levels of IFN-γ and IL-12 were not significantly different in either group (n = 10; [Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 6](#fig3s6){ref-type="fig"}), suggesting that CNV is due to sFLT-1 knockdown rather than non-specific immune activation.

Selective Cre/*lox* FLT-1 ablation induces CNV and RAP {#s2-5}
------------------------------------------------------

The third strategy was genomic deletion. We suppressed sFLT-1 by a Cre/*lox*-mediated conditional gene ablation because *Flt-1* deletion is lethal ([@bib16]). Subretinal injection of pCre in *Flt-1*^*lox/lox*^ mice reduced sFLT-1, induced CNV (n = 10; p*\<*0.01), and increased free VEGF-A in the RPE/choroid (n = 8; p\<0.01) ([Figure 4A](#fig4){ref-type="fig"}).10.7554/eLife.00324.020Figure 4.Suppression of soluble *Flt-1* by conditional *Cre/lox*-mediated *Flt-1* gene ablation induced CNV.(**A**) Western blot from the retinal pigment epithelium (RPE)/choroid tissue confirmed sFLT-1 knockdown by pCre. Subretinal injection of pCre induced CNV and increased VEGF-A levels in *Flt-1*^*lox/lox*^ mice (2 weeks; arrows point to CNV). Representative FA images showed CNV lesions in both the pCre and pNull groups (left bottom). (**B**) Deletion of tomato fluorescence showed that Cre expression (mosaic pattern) was restricted to RPE in transgenic mT/mg *vmd*~*2*~*-cre*^*+*^ mice (at 4 weeks of age) and was restricted to photoreceptors in transgenic mT/mG *iCre-75*^*+*^ mice (at 4 weeks of age), respectively (arrows point to the location of Cre expression). (**C**) Representative FA and OCT (bottom) images showed in vivo that a homozygous RPE-specific *Flt-1* knockout (*Vmd*~*2*~-c*re*^*+*^*flt-1*^*lox/lox*^) mouse (48 days old) developed CNV spontaneously without surgical injury, and a homozygous photoreceptor-specific *Flt-1* knockout mouse (*iCre-75*^*+*^*flt-1*^*lox/lox*^) (30 days old) developed retinal angiomatous proliferation (RAP) spontaneously without surgical injury. The littermate controls without loxp were normal. (**D**) Representative IHC images (top panels) showed the retinal neovessels in the above *Vmd*~*2*~-c*re*^*+*^*flt-1*^*lox/lox*^ (CNV) mouse at 3 months of age. The littermate controls without loxp were normal (red stained vessels). In situ hybridization (middle panels, blue stained *sFlt-1*) and IHC images (bottom panels, red stained sFLT-1) showed decreased expression of sFLT-1 RNA and protein in the RPE (*Vmd*~*2*~-c*re*^*+*^*flt-1*^*lox/lox*^) (arrows). (**E**) Representative IHC images (top panels) showed the retinal neovessels in the above *iCre-75*^*+*^*flt-1*^*lox/lox*^ mouse (RAP) at 3 months of age. The littermate controls without loxp were normal (red stained vessels). In situ hybridization (middle panels, blue stained *sFlt-1*) and IHC images (bottom panels, red stained sFLT-1) showed decreased expression of sFLT-1 RNA and protein in the photoreceptors (*iCre-75*^*+*^*flt-1*^*lox/lox*^) (arrows). Scale bar: 100 µm. CNV: choroidal neovascularization; FA: fluorescein angiography; IHC: immunohistochemistry; IN: inner nuclear layer; OCT: optical coherence tomography; ON: outer nuclear layer; OS: outer segment layer.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.020](10.7554/eLife.00324.020)10.7554/eLife.00324.021Figure 4---figure supplement 1.Genotyping of RPE-specific *Flt-1* knockout mice (obtained by cross-breeding with *Vmd*~*2*~*-cre*^+^ mice and *Flt-1*^*lox/lox*^ mice) with PCR.Lanes 1--3: heterozygous (*Flt-1*^*lox/+*^), homozygous (*Flt-1*^*lox/lox*^), and wild type (*Flt-1*^*+/+*^), respectively. Lanes 4 and 5: *cre*^*−*^ and *cre*^+^, respectively. Lanes 6 and 7: *rtTA*^*−*^ and *rtTA*^*+*^, respectively. RPE: retinal pigment epithelium.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.021](10.7554/eLife.00324.021)10.7554/eLife.00324.022Figure 4---figure supplement 2.Representative RT-PCR shows Cre expression in a *Vmd*~*2*~*-cre*^+^ *flt-1*^+/+^ mouse (lane 2).No Cre expression was observed in wild type mice (lane 1).**DOI:** [http://dx.doi.org/10.7554/eLife.00324.022](10.7554/eLife.00324.022)10.7554/eLife.00324.023Figure 4---figure supplement 3.CNV progression in homozygous RPE-specific *Flt-1* knockout (*Vmd*~*2*~*-cre*^+^*flt-1*^*lox/lox*^) mice.Representative FA images (at same time after fluorescence injection) from a 38 day old mouse demonstrate that CNV lesions appear 8 days after initial imaging in previously non-fluorescent areas, indicating progression of CNV. CNV: choroidal neovascularization; FA: fluorescein angiography; RPE: retinal pigment epithelium.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.023](10.7554/eLife.00324.023)10.7554/eLife.00324.024Figure 4---figure supplement 4.Representative toluidine blue staining images show CNV in a homozygous conditional *Flt-1* knockout mouse (*Vmd*~*2*~*-cre*^*+*^*flt-1*^*lox/lox*^, 3 months old) compared to normal retinal morphology in a littermate control.CNV: choroidal neovascularization; IS: inner segment layer; ON: outer nuclear layer; OS: outer segment layer; RPE: retinal pigment epithelium.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.024](10.7554/eLife.00324.024)10.7554/eLife.00324.025Figure 4---figure supplement 5.Representative TEM images show CNV in a homozygous conditional *Flt-1* knockout mouse (*Vmd*~*2*~*-cre*^*+*^*flt-1*^*lox/lox*^) compared to normal retinal architecture in a littermate control.CC: choriocapillaris; CNV: choroidal neovascularization; TEM: transmission electron microscopy; RPE: retinal pigment epithelium.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.025](10.7554/eLife.00324.025)10.7554/eLife.00324.026Figure 4---figure supplement 6.Representative western blot shows increased VEGF-A levels in the RPE/choroid of a *Vmd*~*2*~*-cre*^*+*^*flt-1*^*lox/+*^ mouse with CNV (lane 2) compared to a littermate control (*Vmd*~*2*~*-cre*^*+*^*flt-1*^*+/+*^) without CNV (lane 1).CNV: choroidal neovascularization; RPE; retinal pigment epithelium.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.026](10.7554/eLife.00324.026)10.7554/eLife.00324.027Figure 4---figure supplement 7.Early vascular changes with normal retinal structures occur in homozygous conditional *Flt-1* knockout mice (*Vmd*~*2*~*-cre*^*+*^*flt-1*^*lox/lox*^).Top panels: Toluidine blue staining images show the morphology of the retina. There are no significant changes in the retina structure. There is a bump (frame) in the RPE layer in a homozygous conditional *Flt-1* knockout mouse (*Vmd*~*2*~*-cre*^*+*^*flt-1*^*lox/lox*^) compared to littermate control. Middle and bottom panels (magnified transmission electron microscopy images of the corresponding frames): There is an elongated profile (asterisk) within Bruch\'s membrane that is consistent with a tongue of endothelial cell cytoplasm by its electron density. There is a nucleus on the external side of the choriocapillary, and it is separated from the endothelial lining by a basement membrane. Bruch\'s membrane is intact. This is consistent with nascent choroidal endothelial changes preceding the development of frank CNV breaching Bruch\'s membrane. Br: Bruch\'s membrane; Ch: choroid; CNV: choroidal neovascularization; OS: outer segment layer; RBC: red blood cell; RPE: retinal pigment epithelium.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.027](10.7554/eLife.00324.027)10.7554/eLife.00324.028Figure 4---figure supplement 8.FA images show that no CNV has developed in homozygous conditional *Flt-1* knockout mice (*Vmd*~*2*~*-cre*^*+*^*flt-1*^*lox/lox*^) at p21.CNV: choroidal neovascularization; FA: fluorescein angiography.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.028](10.7554/eLife.00324.028)10.7554/eLife.00324.029Figure 4---figure supplement 9.Toluidine blue staining images show the morphology of the retina at p28.Most areas of retina are normal in *Vmd*~*2*~*-cre*^*+*^*flt-1*^*lox/lox*^ mice. In a CNV lesion, the overlying neuronal outer nuclear layer is mainly intact. Scale bar: 10 µm. CNV: choroidal neovascularization.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.029](10.7554/eLife.00324.029)

To avoid the effects of mechanical disruption of the retina by subretinal injection (as shown in PBS or sham controls above), we performed conditional ablation of *Flt-1* in the RPE or photoreceptors to determine whether CNV or RAP could be induced without injury. We interbred transgenic *Vmd*~*2*~-*cre*^*+*^ mice (Cre recombinase expressed specifically in RPE) ([@bib35]) or *iCre-75*^*+*^ mice (Cre recombinase expressed specifically in photoreceptors) ([@bib35]) with floxed *Flt-1* mice. Cre expression in the two Cre lines was identified by interbreeding with mT/mG mice, which express tomato/EGFP in all tissues ([Figure 4B](#fig4){ref-type="fig"}). The results showed that Cre expression, as indicated by tomato deletion resulting in exclusive *Egfp* fluorescence, was restricted to the RPE in floxed mT/mG mice bred with *Vmd*~*2*~*-cre*^*+*^ and to the photoreceptors in floxed mT/mG mice crossed with the *iCre-75*^*+*^ line ([Figure 4B](#fig4){ref-type="fig"}).

At 1--3 months of age, nearly all homozygous RPE-specific *Flt-1* knockout mice (*Vmd*~*2*~*-cre*^*+*^*flt-1*^*lox/lox*^) (18/22 eyes, 82%; p\<0.001), and about half of the heterozygous conditional *Flt-1* knockout mice (*Vmd*~*2*~*-cre*^+^*flt-1*^*lox/+*^) (17/42 eyes, 40%; p*=*0.009) developed CNV, which progressed over time, compared with 18% (2/22 eyes, 9%) of littermate controls (*Vmd*~*2*~*-cre*^*+*^*flt-1*^*+/+*^). Similarly, at 1--3 months of age, both homozygous (*iCre-75*^*+*^*flt-1*^*lox/lox*^, 8/14 eyes, 57%; p*\<*0.05) and heterozygous (13/24 eyes, 54%; p*\<*0.05) photoreceptor-specific *Flt-1* knockout mice (*iCre-75*^*+*^*flt-1*^*lox/+*^) developed RAP, compared with 10% (1/10 eyes) of littermate controls (*iCre-75*^*+*^*flt-1*^*+/+*^). The number of lesions with leakages on FA ranged from one to four per eye in the floxed animals, whereas in littermate controls, there was no more than one neovascular lesion per eye. RAP lesions started from the inner retina (arising from retinal vessels) at an early stage and invaded the photoreceptor layer, eventually anastomosing with the choroidal neovasculature ([Figure 4C--E](#fig4){ref-type="fig"}, [Figure 4---figure supplements 1--5](#fig4s1 fig4s2 fig4s3 fig4s4 fig4s5){ref-type="fig"} and [Tables 2 and 3](#tbl2 tbl3){ref-type="table"}).10.7554/eLife.00324.030Table 2.Transgenic mice with Cre/*lox*-mediated conditional gene ablation of *Flt-1* in the retinal pigment epithelium (RPE) developed choroidal neovascularization (CNV) (\<3 months old)**DOI:** [http://dx.doi.org/10.7554/eLife.00324.030](10.7554/eLife.00324.030)homozygous (*Vmd*~*2*~-*cre*^*+*^ *flt-1*^*lox/lox*^)heterozygous (*Vmd*~*2*~-*cre*^*+*^ *flt-1*^*lox/+*^)littermate control (*Vmd*~*2*~-*cre*^*+*^ *flt-1*^*+/+*^)Litter 11/1 mice, 2/2 eyesNANALitter 22/2 mice, 3/4 eyes5/7 mice, 9/14 eyes0/1 mouse 0/2 eyesLitter 31/1 mouse, 2/2 eyes1/2 mice, 1/4 eyesNALitter 41/1 mouse, 2/2 eyes2/3 mice, 2/6 eyesNALitter 52/2 mice, 4/4 eyes1/2 mice, 1/4 eyes1/2 mice, 1/4 eyesLitter 63/3 mice, 4/6 eyes1/2 mice, 1/4 eyes1/5 mice, 1/10 eyesLitter 71/1 mouse, 1/2 eyes2/5 mice, 3/10 eyes0/3 mice, 1/6 eyesTotal11/11 mice (100%)12/21 mice (57%)2/11 mice (18%)18/22 eyes (82%, p*=* 1.3E-6)17/42 (40%, p=0.009)2/22 eyes (9%)10.7554/eLife.00324.031Table 3.Transgenic mice with Cre/*lox*-mediated conditional gene ablation of *Flt-1* in the photoreceptors developed retinal angiomatous proliferation (RAP) (\<3 months old)**DOI:** [http://dx.doi.org/10.7554/eLife.00324.031](10.7554/eLife.00324.031)homozygous (*iCre-75*^*+*^ *flt-1*^*lox/lox*^)heterozygous (*iCre-75*^*+*^ *flt-1*^*lox/+*^)littermate control (*iCre-75*^*+*^ *flt-1*^*+/+*^)Litter 12/4 mice, 3/8 eyesNA0/1 mouse 0/2 eyesLitter 21/1 mice, 1/2 eyes3/4 mice, 6/8 eyesNALitter 31/1 mouse, 2/2 eyes2/4 mice, 4/8 eyes0/1 mouse, 0/2 eyesLitter 41/1 mice, 2/2 eyes1/2 mice, 1/4 eyes1/2 mice, 1/4 eyesLitter 5NA1/1 mouse, 2/2 eyesNALitter 6NA0/1 mouse, 0/2 eyes0/1 mouse, 0/2 eyesTotal6/7 mice (86%)7/12 mice (58%)1/5 mice (20%)8 /14 eyes (57%, p*\<0.05*)13/24 (54%, p\<0.05)1/10 eyes (10%)

We observed rare CNV occurrences in the littermate controls. These results may be accounted for by Cre 'leakiness' or toxicity, which has been reported in several transgenic models using the Cre-lox system ([@bib14]; [@bib50]).

We further confirmed that sFLT-1 was down-regulated by in situ hybridization and IHC, while VEGF-A was up-regulated by western blotting in the conditional *Flt-1* knockout mice, compared with littermate controls ([Figure 4D,E](#fig4){ref-type="fig"}, [Figure 4---figure supplement 6](#fig4s6){ref-type="fig"}), suggesting CNV/RAP occurrence is due to sFLT-1 knockdown in the RPE or photoreceptors. We observed no changes in sFLT-1 expression in the inner retinae of the two conditional *Flt-1* knockouts. However, sFLT-1 expression was somewhat decreased in the inner retina following subretinal injection with AAV.shRNA.*sFlt-1*. This may be due to diffusion and leakage of the injection fluid along the injection track.

Although there are several inherited retinal degeneration models with changes in RPE/photoreceptors where CNV does not develop, it is theoretically possible that pathological disturbances in RPE or photoreceptors due to *Flt-1* knockout may themselves contribute to the development of CNV. Furthermore, CNV by its nature is anatomically disruptive to the RPE which in turn leads to photoreceptor disruption. To determine whether the CNV/RAP lesions we observed were due to preceding retinal changes, we performed IHC staining on sections of VMD-*Creflt*^*loxp/loxp*^ mice at p7, p14, and p21. No CNV lesions were seen on retinal sections at these timepoints. However, we found evidence of nascent choroidal endothelial changes abutting Bruch's membrane at p21 ([Figure 4---figure supplement 8](#fig4s8){ref-type="fig"}). At p21, the earliest feasible timepoint for angiography, we observed no CNV on FA ([Figure 4---figure supplement 9](#fig4s9){ref-type="fig"}). The earliest timepoint that we detected CNV angiographically was at p28 ([Figure 4---figure supplement 9](#fig4s9){ref-type="fig"}). Taken together, these data indicate early choroidal vascular changes without changes in the overlying neural retina.

It is important to note that we cannot exclude sFLT-1 production originating from proteolytic cleavage. To the best of our knowledge, ADAM10 is the only described protease that cleaves membrane-bound FLT-1 to the soluble isoform ([@bib58]). We found that ADAM10 is expressed in the inner retinal layers ([Figure 5](#fig5){ref-type="fig"}), but not in the RPE or photoreceptors where we found that knockdown of sFLT-1 breached photoreceptor avascular privilege. Hence, a proteolytic cleavage-mediated origin for outer retinal sFLT-1 is unlikely.10.7554/eLife.00324.032Figure 5.Representative IHC staining images show the ADAM10 expression in the inner layer of the retina.IHC: immunohistochemistry; IN: inner nuclear layer; IP: inner plexiform layer; ON: outer nuclear layer; RPE: retinal pigment epithelium.**DOI:** [http://dx.doi.org/10.7554/eLife.00324.032](10.7554/eLife.00324.032)

Discussion {#s3}
==========

The neovascular processes we observed, either of CNV or RAP phenotypes in RPE/photoreceptor-specific *Flt-1* knockout mice, recapitulate many of the characteristics of human CNV or RAP (different subtypes of AMD) ([@bib13]). In contrast to the transgenic mice which develop CNV in senility ([@bib3]; [@bib23]; [@bib59]) or a model of RAP in the systemic VLDLR^−/−^ mouse ([@bib20]), the mouse models presented herein exhibit CNV or RAP in heterozygous transgenic mice as well and within a rapid timeframe, indicating the vital role of sFLT-1 in maintaining the integrity of photoreceptor avascular privilege. Moreover, previous studies found that transgenic mice which overexpress VEGF-A in either RPE or photoreceptors developed intrachoroidal neovascularization or retinal neovascularization but not CNV or RAP ([@bib42]; [@bib52]). These phenomena suggest that overexpression of VEGF-A in the retina or RPE is not sufficient to overcome the subretinal vascular barrier to induce CNV. On the other hand, in our study, mice with reduced sFLT-1 expression in the RPE developed CNV, indicating that sFLT-1 down-regulation is sufficient to cause CNV. Hence, the ratio of soluble FLT-1 to VEGF is likely critical to the maintenance of the subretinal vascular barrier. We believe physiologic sFLT-1 is not disruptive to normal neural function due to both a critical balance and the polarity of sFLT-1 expression by RPE. Further, the models presented herein more closely mimic human AMD, rendering these transgenic models quite useful for further studies and translational applications.

While diffusion of sFLT-1 between the RPE and photoreceptors is theoretically possible, the intervening interphotoreceptor matrix could trap sFLT-1, preventing free diffusion. In addition, sFLT-1 secretion by the RPE is polarized basally towards the choroid; therefore, VEGF secretion from the RPE can elicit choroidal neovascularization.

We observed less CNV in the injection site after AAV.shRNA.*sFlt-1* delivery than after antibody or genomic knockdown; this may be due to persistence of preformed sFLT-1, as the turnover of this protein in the RPE is, to our knowledge, unknown. Another interesting observation is that lower levels of both VEGF-A and CNV were observed in *Vegfa*^*lox/lox*^ mice compared with wild type mice in AAV-mediated sFlt-1 knockdown studies. It is possible that the insertion of lox sites flanking the *VEGF-A* gene can affect gene expression in conditions of injury. This could be due to several mechanisms including disruption of cis-regulatory elements, interruption of unknown miRNA binding sites, and effects on mRNA stability by the palindromic nature of loxp sites. Loxp insertion has previously been reported to affect the transcription of genes in cis in selected circumstances ([@bib54]; [@bib41]).

Nonetheless, taken together, our findings demonstrate that protein blockade, transcriptional silencing, or genomic ablation of sFLT-1 can induce CNV/RAP, showing that sFLT-1, through sequestration of VEGF-A, is a key molecular defender of vision-critical photoreceptor avascular privilege. Our transgenic models would not be expected to directly affect *Flt-1* expression in retinal or choroidal vessels. However, the knockdown of *Flt-1* in photoreceptors in our *iCre-75*^*+*^*flt-1*^*lox/lox*^ mice may contribute to focal areas of photoreceptor degeneration due to the depletion of *Flt-1* compromising Wnt signaling.

Reduced VEGF-A expression has been observed in CNV specimens surgically obtained from patients with persistent CNV not responsive to anti-VEGF-A therapy. This reduction may explain why some patients stop responding to anti-VEGF-A therapy after a period of time ([@bib55]). Endothelial sFLT-1 expression is regulated by VEGF, acts as an autocrine regulator of endothelial cell function, and controls angiogenesis ([@bib2]). An important area of future investigation will be to determine, based on stage of CNV development, how anti-VEGF-A therapy can be complemented both with approaches to suppress underlying hypoxia and inflammation and with strategies to maintain or increase sFLT-1 expression, perhaps revitalizing normal vascular barriers.

The milieu in the photoreceptor/RPE/Bruch's membrane/choriocapillaris is complicated. Some endogenous angiogenesis inhibitors (e.g., pigment epithelium-derived factor) in the RPE/Bruch's membrane/choriocapillaris complex have been reported to be reduced in AMD and may contribute to the barrier against choroidal neovascular invasion ([@bib9]). Nevertheless, the findings in this study offer greater insight into the molecular mechanisms responsible for retinal vascular demarcations and CNV/RAP, and the described molecular advances have broader ramifications. They impact testing of anti-angiogenic pharmaceuticals, may illuminate the mechanistic basis of angiogenesis in other diseases affecting over a billion people ([@bib44]), hold translational import for a key cause of blindness, and support the ongoing clinical trial of AAV.*sFlt-1* for the treatment of neovascular AMD (clinical trial NCT01024998 at [www.clinicaltrials.gov](http://www.clinicaltrials.gov)). Further, they highlight a potential use of sFLT-1 as a therapeutic target in situations where angiogenesis is desirable, as well as a new role for sFLT-1, which has recently been found to protect renal podocytes ([@bib24]), and the genetic models of AMD we describe are the first which exhibit CNV or RAP spontaneously at an early age, rendering them original non-invasive platform technologies with a variety of applications.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

C57BL/6J mice (6--8 weeks; The Jackson Laboratory, Bar Harbor, ME), Balb/cJ mice (6 weeks; The Jackson Laboratory), *Vegfa*^*lox/lox*^ mice ([@bib18]) (6--8 weeks, C57BL/6 background; gift of Genentech, San Francisco, CA), *Tlr3*^*−/−*^ mice (6--8 weeks, B6;129S1-*Tlr3*^*tm1Flv*^/J; The Jackson Laboratory), *Flt-1*^*lox/lox*^ mice ([@bib8]) (6--8 weeks, gift of Genentech), *Vmd*~*2*~*-cre* mice ([@bib35]) (8--10 weeks, FVB/N mice background, heterozygotes do not have any RD1 mutation; Cre expression in RPE continues from embryonic day 9 to postnatal day 60; gift of Dr Yun Zheng Le, University of Oklahoma Health Sciences Center), *iCre-75*^*+*^ mice ([@bib36]) (14--20 weeks, C57BL/6 × SJL background; Cre expression in photoreceptors begins earlier than postnatal day 11; gift of Dr Ching-Kang Chen, University of Utah), mT/mG mice (14--20 weeks; STOCK *Gt(ROSA)26Sor*^*tm4(ACTB-tdTomato,-EGFP)Luo*^/J; The Jackson Laboratory) and *Flt-1Tk*^*−/−*^ mice (14--20 weeks) ([@bib21]) were used. Experimental groups were age and sex matched. To identify Cre expression in the RPE layer of *Vmd*~*2*~*-cre*^*+*^ ([@bib35]) or photoreceptor layer of *iCre-75*^*+*^ mice ([@bib36]), the mT/mG mice which express tomato/EGFP in all tissues were interbred with the above lines, respectively and the deletion of tomato fluorescence was checked at the age of 4 weeks. To generate RPE (or photoreceptor) specific *Flt-1* knockout mice, *Vmd*~*2*~*-cre*^*+*^ (or *iCre-75*^*+*^) mice and *Flt-1*^*lox/lox*^ mice were cross-bred to obtain the homozygous (*Vmd*~*2*~*-creflt-1*^*lox/lox*^ or *iCre-75*^*+*^ *flt-1*^*lox/lox*^), heterozygous (*Vmd*~*2*~*-cre*^*+*^ *flt-1*^*lox/+*^ or *iCre-75*^*+*^ *flt-1*^*lox/+*^), and littermate controls (*Vmd*~*2*~*-cre*^*+*^*flt-1*^*+/+*^ or *iCre-75*^*+*^*flt-1*^*+/+*^). These mice were identified with genotyping as described ([@bib36]; [@bib35]).

All mice were age and sex matched (mice used for subretinal injection were 6--8 weeks old and male) and fed with autoclaved 8656 Teklad Sterilizable Rodent diet provided by Harlan Laboratories (Indianapolis, IN). Cages were routinely changed once every 2 weeks throughout the course of this study. Experiments were approved by the University of Utah Institutional Animal Care and Use Committee and conformed to the Association for Research in Vision and Ophthalmology Statement on Animal Research.

Human samples {#s4-2}
-------------

Normal human fresh globes were obtained within 4 hr of death from the Utah Lions Eye Bank, and sections were prepared as described below. Cryosection slides (12 µm or 5 µm thickness) of human ocular AMD and normal control tissue were obtained from the Ambati Laboratory at the University of Kentucky. AMD tissue and normal human tissue was matched for gender and age in each case. Specimens were taken from the eyes of AMD patients who had never received anti-VEGF antibody (Lucentis or Avastin) therapy.

Vectors {#s4-3}
-------

AAV.shRNA.*sFlt-1* was developed as previously described ([@bib5]). In brief, short hairpin (sh)RNA expression cassettes (SECs) were developed by in vitro PCR amplification. SECs are PCR products that consist of promoter and terminator sequences flanking a hairpin siRNA template. Multiple target sequences along with different combinations of promoters were screened to identify the most effective siRNA capable of gene knockdown in vitro and in vivo. We used pAAV-MCS plasmids (AAV Helper-Free System; Agilent Technologies, Santa Clara, CA) containing inverted terminal repeats ([@bib37]). We obtained Ac*Gfp* cDNA from pIRES2-Ac*Gfp1* (Clontech Laboratories, Mountain View, CA), and generated pAAV-Ac*Gfp* to insert Ac*Gfp* cDNA into the multi-cloning site of pAAV-MCS. sh*Flt* and shNegative cDNA with an H1 promoter were inserted into pAAV-Ac*Gfp* using a PstI site to obtain pAAV-Ac*Gfp*-sh*Flt* and pAAV-Ac*Gfp*-shNegative. Serotype 2 AAV vector containing plasmids were produced by the Viral Vector Core at the University of Massachusetts Medical School. The target (sFLT-1) sequence is aatgattgtaccacacaaagt. A target for shRNA in identical regions of human and mouse soluble FLT-1 unique intron 13 derived tail was selected, since the intron 13 derived tail of 31 amino acids is only present in soluble FLT-1 and not in membrane FLT-1, so soluble FLT-1 was specifically abrogated.

Locked nucleic acid probes {#s4-4}
--------------------------

A 21 base DNA oligonucleotide with 30% locked nucleic acid (LNA; Exiqon, Woburn, MA) substitutions was used as an anti-sense probe against sFLT-1 mRNA. The sequence of the LNA probe was actttgtgtggtacaatcatt. The calculated RNA Tm value is 46°C. A 21-mer sFLT-1-sense-LNA probe with a sequence aatgattgtaccacacaaagtc (predicted RNA Tm value of 46°C) was used as control. Both LNA probes were digoxigenin ([@bib27]) labeled at the 5′ and 3′ ends.

Subretinal injection {#s4-5}
--------------------

Mice were placed under general anesthesia with an intraperitoneal injection of tribromoethanol (289 mg/kg). Topical 0.5% proparacaine solution and 1% tropicamide ophthalmic solution obtained from the Moran Eye Center pharmacy were applied to the cornea as an anesthetic and dilator, respectively. Using an Olympus stereomicroscope for magnification, a small incision was made behind the limbus with a 30.5 gauge needle. To deliver 1 μl of each treatment, a custom 33 gauge, blunt tipped microsyringe (Hamilton, Reno, NV) was inserted through the incision, vitreous, and retina into the subretinal space in the posterior pole of the retina, taking care to avoid the lens. Fundus examinations during the injection procedure showed partial retinal detachment, confirming successful subretinal delivery.

To inhibit sFLT-1 by shRNA in C57BL/6J mice, 1 µl of AAV.shRNA.s*Flt-1.Gfp* (1.4 × 10^11^ genomic copies/ml) was injected subretinally, with AAV.shRNA.*Gfp* (1.4 × 10^11^ genomic copies/ml), AAV.*Gfp* (1.4 × 10^11^ genomic copies/ml) or PBS injected as controls.

For genomic deletion in *Flt-1*^*lox/lox*^ mice, a plasmid encoding Cre recombinase (pCre; 1 µg, gift of RK Nordeen, University of Colorado) with 10% NeuroPORTER Transfection Reagent (Genlantis, San Diego, CA) as a plasmid transfection enhancer ([@bib26]) was injected into the subretinal space. Analogous empty plasmid (pNull, 1 µg) with 10% NeuroPORTER was injected as a control.

For genomic deletion in *Vegfa*^*lox/lox*^ mice, 1 µl of 50% pCre, 10% NeuroPORTER, and 40% AAV.shRNA.*sFlt-1*.*Gfp* was injected into the subretinal space. As controls, 1 µl of the following vectors were injected into the subretinal space of *Vegfa*^*lox/lox*^ mice: (1) 50% pNull, 10% NeuroPORTER, and 40% AAV.shRNA.*sFlt-1.Gfp*; (2) 50% pCre, 10% NeuroPORTER, and 40% AAV.shRNA.*Gfp*; (3) 50% pCre, 10% NeuroPORTER, and 40% AAV.*Gfp*; or (4) 50% pCre, 10% NeuroPORTER, and 40% 1× PBS.

A 1 µl (0.2 µg) sample of goat FLT-1 antibody (mouse myeloma cell line NSO derived recombinant mouse VEGFR1, Ser27Glu759; R&D Systems, Minneapolis, MN) or equivalent goat isotype IgG (Jackson ImmunoResearch, West Grove, PA) as control were subretinally injected into C57BL/6J, *Flt-1tk*^−/−^, or *Tlr3*^*−/−*^ mice, respectively.

CNV observation in vivo {#s4-6}
-----------------------

Mice were anesthetized with tribromoethanol (289 mg/kg) and the pupils were dilated with topical 1% tropicamide ophthalmic solution (Bausch & Lomb, Rochester, NY). All in vivo imaging described was performed using a Spectralis confocal ophthalmoscope (Heidelberg Engineering, Vista, CA). HRA-OCT imaging of mouse fundi was performed 2, 4, 6, and 10 weeks after subretinal injections with AAV.shRNA.*sFlt-1*, or at 21 days, 1, 2, and 3 months of age in the transgenic mice. Green fluorescent protein (GFP) expression was observed with a red free or autofluorescence filter. Mice were intraperitoneally injected with 0.1 ml of 10% sodium fluorescein (Akorn, Lake Forest, IL) or 0.2 ml of 8 mg/ml indocyanine green (ICG, Akorn). CNV was evaluated by experienced retinal specialists using a combination of images obtained by FA, optical coherence tomography (OCT), ICG, or a MICRON II small animal retinal imaging microscope (Phoenix Research Laboratories, San Ramon, CA).

Computer-assisted quantitative analysis of OCT images {#s4-7}
-----------------------------------------------------

Quantification of lesions in vivo was performed by using OCT images according to established procedures ([@bib51]; [@bib25]; [@bib17]; [@bib46]; [@bib19]; [@bib39]). This method has been widely used for estimating CNV volumes in vivo, especially in AMD patients, and has proved to be a highly reproducible quantitative measurement ([@bib25]; [@bib19]; [@bib39]). B-scans were exported from Heidelberg Eye Explorer (HEE), Heidelberg's image analysis software, in .jpeg format and imported as complete stacks into Seg3D software. Seg3D is a segmentation processing and analyzing tool developed by the University of Utah Scientific Computing and Imaging Institute and the NIH/NCRR Center for Integrative Biomedical Computing (Volumetric Image Segmentation and Visualization, Scientific Computing and Imaging Institute \[[@bib17]\], available at <http://www.seg3d.org>). Boundaries of the CNV lesion and deformations of the RPE were manually outlined using a polyline tool by a masked and experienced technician ([@bib39]; [@bib56]). Seg3D masked the region enclosed within the polyline for each consecutive b-scan in pixels squared. An automated feature of Seg3D calculated two-dimensional lesion area, summing the masked b-scans for each stack. Scaling factors obtained from HEE were used to convert pixel^2^ to μm^2^. After adjusting for murine corneal curvature to 1.4 mm ([@bib1]), the scaling factors for both x- and z-axes were 1.45 ± 2 and 3.87 μm/pixel, respectively. To calculate lesion volume (μm^3^), the lesional area on each scan line was multiplied by the distance between scans (52 ± 2 μm; provided by HEE software), and then summated. Finally, estimated volumes were converted to mm^3^ and reported.

CNV was quantified by FA (at 3--5 min after fluorescein injection) and OCT 10 days after antibody injection and 4 weeks after injection of AAV.shRNA.*sFlt-1*.

Cryosection {#s4-8}
-----------

The eyes were enucleated, fixed in 4% paraformaldehyde (PFA) (Electron Microscopy Sciences, Hatfield, PA) for 2 hr at 4°C, cryoprotected in 30% sucrose overnight, and embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek USA, Torrance, CA). Sections (12 µm) were cut on a cryostat.

Immunohistochemistry {#s4-9}
--------------------

Rabbit sFLT-1 primary antibody ([@bib43]) (0.03 µg/µl, rabbit anti‐C‐terminal of sFLT-1) was provided by Drs Lacal and Orecchia, Instituto Dermopatico dell'Immacolata, Instituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), Rome, Italy. The same concentrations of rabbit IgG (Invitrogen, Carlsbad, CA) were used as isotype controls. The Vector M.O.M. (Mouse on Mouse) immunodetection kit (Vector Laboratories, Burlingame, CA) was used to detect mouse antibody on mouse tissue according to the manufacturer's instructions. To quench autofluorescence, 0.3% Sudan Black (wt/vol) (Sigma-Aldrich, St. Louis, MO) in 70% EtOH (vol/vol) was applied to slides; Dylight 405 (1:100; Jackson ImmunoResearch) was used as a secondary antibody to avoid RPE autofluorescence without Sudan Black application.

To determine sFLT-1 and/or VEGF expression in mice, sections were blocked in 10% goat serum (Abcam, Cambridge, MA) diluted in IHC buffer (1% BSA, 1% FBS, and 0.3% Triton X-100 in PBS pH 7.4) for 1 hr followed by overnight incubation with rabbit sFLT-1 primary antibody and/or mouse anti-VEGF monoclonal antibody (1:100; Abcam) diluted in blocking solution. The Vector M.O.M. immunodetection kit was used to detect mouse antibody on mouse tissue according to the manufacturer's instructions. After primary antibody incubation, slides were washed and incubated in secondary antibody Alexa Fluor 488 goat anti-rabbit (1:400; Invitrogen) and/or Alexa Fluor 546 goat anti-mouse (1:400; Invitrogen) for 1 hr at room temperature (RT). After washing three times with PBS, VECTASHIELD Mounting Medium with DAPI (Vector Laboratories) was applied and slides were coverslipped. The same concentrations of rabbit IgG were used as isotype controls.

To determine sFLT-1 and/or VEGF expression in human tissue, the same primary secondary antibodies were used as above. After secondary antibody application, 0.3% Sudan Black (wt/vol) was applied to slides for 10 min to quench autofluorescence. Slides were rinsed quickly with PBS eight times and mounted. Dylight 405 was used instead of the above secondary antibody to avoid the RPE autofluorescence without Sudan Black application.

To demonstrate vessels in the human sections, rat anti-heparan sulfate proteoglycan (perlecan) monoclonal antibody (1:200, clone A7L6; Millipore, Billerica, MA) was used as primary antibody, and anti-rat IgG-FITC (1:1000, F6258; Sigma-Aldrich) was used as secondary antibody, followed by Sudan Black staining as describe above. VECTASHIELD Mounting Medium with DAPI was used and the slides were coverslipped.

Histology {#s4-10}
---------

Hematoxylin and eosin (H&E) staining, toluidine blue staining, and transmission electron microscopy followed the protocols (<http://prometheus.med.utah.edu/~marclab/marclab_09_tools-protocols.html>) ([@bib39]). Samples were sectioned at 1 μm for H&E staining or toluidine blue staining. The following materials were used: 10% neutral buffered formalin (EMD Chemicals USA, Gibbstown, NJ), hematoxylin solution (Sigma-Aldrich), acid alcohol (Thermo Scientific, Waltham, MA), Bluing Reagent (0.25 NH~4~ solution; Richard-Allan Scientific, Kalamazoo, MI), Eosin solution (Sigma-Aldrich), and Cytoseal XYL (Fisher Scientific, Pittsburgh, PA).

### Toluidine blue staining {#s4-10-1}

Sections were cut at 1 μm, transferred with a drop of distilled water onto a glass slide, and then dried on a slide warmer. After the sections were completely dried, they were covered with a few drop of toluidine blue solution (0.05% toluidine blue and 1% sodium borate in distilled water, mixed at a ratio of 1:2 with the heat source still on) for 1--2 min, then excess solution was soaked up and the slide was air-dried, followed by coverslipping with the above mounting medium.

### ADAM10 staining {#s4-10-2}

Cryosections (12 μm) from day 3 of laser induced CNV murine eyes were incubated at 37°C for 40 min. After washing with PBS twice, the sections were incubated in 0.25% Triton X-100/PBS for 15 min at RT. After washing with PBS twice, the sections were blocked in 5% donkey serum/0.02% Triton X-100/PBS for 30 min at RT. Primary antibody (Abcam ab1997 for ADAM10; Invitrogen 02-6102 for isotype) was applied to the section at 5 μg/ml in blocking buffer, and incubated for 1 hr at RT. After washing with PBS five times, 1:1000 Alexa546 conjugated donkey anti-rabbit IgG Fab fragment (Invitrogen A11071) was applied to the section, and incubated for 30 min at RT. After washing with PBS three times, the nucleous was stained with Hoechest33342 (Invitrogen) and the sections were then mounted. Images were taken with an inverted fluorescence microscope ([@bib32]).

### Transmission electron microscopy {#s4-10-3}

Fixed tissues were osmicated for 45--60 min in 0.5--1% OsO~4~ in 0.1 M cacodylate buffer, processed in maleate buffer for staining with uranyl acetate, and resin-embedded. Ultrathin sections were cut at 60 nm with a Leica ultramicrotome and imaged at 80 KeV on a JEOL JEM 1400 electron microscope. Images were captured with a 16-megapixel GATAN Ultrascan 4000 camera. All fluorescent sections and H&E stained sections were imaged with an Axiovert 200 microscope (Carl Zeiss MicroImaging, Thornwood, NY) equipped with confocal epifluorescence illumination or an AxionCamMR digital camera (Carl Zeiss Microscopy, Thornwood, NY) and processed using Adobe Photoshop software (Adobe Systems, San Jose, CA). Unstained tissue sections were mounted and coverslipped and then directly examined under the above microscopes.

In situ hybridization {#s4-11}
---------------------

Cryosections (12 µm) of BALB/cJ mouse eye tissue were prepared as described above. Sections were fixed in 4% PFA for 10 min followed by 5 µg/ml proteinase-K treatment in DEPC treated water at RT for 10 min. Pre-hybridization was performed in hybridization buffer (50% formamide, 5× SSC, 5× Denhardt's, 250 µg/ml yeast RNA, 500 µg/ml SSD, 2% Roche blocking reagents, and 0.2% Tween 20) at RT for 4 hr, followed by hybridization with 20 nM anti-sense sFLT-1 LNA probe. Hybridization was performed at 55°C. After hybridization, stringent washes were performed at 60°C with 5× SSC for 30 min, 2× SSC for 30 min, 1× SSC for 30 min, and 0.2× SSC for 1 hr. Procedures to avoid RNase contamination were used during the following steps. Slides were blocked in Tris buffer (0.1 M Tris pH 7.5/0.15 M NaCl) containing 10% sheep serum for 1 hr and then incubated in alkaline phosphatase-conjugated anti-digoxigenin antibody (1:2000; Roche Applied Science, Indianapolis, IN) overnight at 4°C. Enzymatic development was performed using 4-nitroblue tetrazolium (NBT) and 5-brom-4-chloro-30-indolylphosphate (BCIP) substrate (Roche Applied Science), forming a dark blue NBT-formazan precipitate within 2--3 hr. Images were obtained with an Axiovert 200 inverted microscope (Carl Zeiss Microscopy). In order to avoid the interruption from dark RPE, white mice lines were used.

Protein expression {#s4-12}
------------------

Mouse RPE and choroid were harvested, placed in 10% RIPA buffer (Sigma-Aldrich) and sonicated 3--5 times. Samples were spun at 14,000×*g* for 15 min and the supernatant, containing total protein extract, was transferred to a clean labeled tube. Tissue supernatant was used to perform all protein assays. Total protein was quantified using a Pierce BCA Protein Assay Kit (ThermoFisher Scientific, Rockford, IL) according to the manufacturer's protocol. Mouse VEGF-A (BMS619; eBioscience, San Diego, CA), mouse IL-12 (KMC0121; Invitrogen), mouse IFN-γ (KMC4021; Invitrogen), and mouse placental growth factor (E0114m; Uscn Life, Wuhan, China) ELISAs were performed according to the manufacturer's instructions to quantify VEGF, IL-12 and IFN-γ, and PlGF, respectively. All assays were read using an ELx800 Absorbance Microplate Reader and Gene5 software (BioTek, Winooski, VT).

SDS-PAGE and western blot {#s4-13}
-------------------------

AAVs or plasmid subretinal injections are described above. Two weeks after the injection, we examined sFLT-1 protein reduction by AAV.shRNA.*sFlt-1* using western blot from the RPE/choroid. After the mice were euthanized, the RPE/choroid complex was separated from the sclera under a stereomicroscope and placed in 120 μl of RIPA buffer (Sigma-Aldrich) containing protease inhibitor cocktail (Roche Applied Science). Samples were homogenized with a sonic dismembrator (ThermoFisher Scientific), and total protein concentration was determined using 10 µl of sample and a Pierce BCA assay kit (ThermoFisher Scientific). The proteins were eluted with Laemmli buffer (Bio-Rad Laboratories, Hercules, CA) on ice for 5 min, boiled for 5 min, and centrifuged at 14,000×*g* for 5 min. Then 10 µg of protein were run through a 10% acrylamide gel under reducing conditions. After SDS-PAGE, proteins were transferred to a nitrocellulose membrane and incubated for 1 hr with blocking buffer (3% BSA and 0.05% Tween 20 in TBS for FLT-1 or 5% non-fat milk and 0.05% Tween 20 in TBS for other proteins) then incubated with anti-FLT-1 antibody targeting D1--D5 of FLT-1 (1:1000, ab9540; Abcam) which recognize sFLT-1 and mFLT-1, or Novagen anti-CRE antibody (1:5000, 69050; EMD Millipore, Billerica, MA) overnight at 4°C. The membrane was washed once in TBST (0.05% Tween 20/TBS) and twice in TBS. Finally, the membrane was incubated with the appropriate secondary HRP-linked antibody in blocking buffer for 30 min at RT. After washing once with TBST and three times with TBS, the membrane was developed using an Amersham ECL Plus Western Blotting Detection Kit (GE Healthcare Bio-Sciences, Piscataway, NJ). Chemiluminescence was detected by a FOTO/Analyst Electronic Imaging System (FOTODYNE, Hartland, WI). As an internal control, a western blot detecting β-actin was performed as follows: the membrane was incubated in Pierce Restore Plus Western Blot Stripping Buffer (ThermoFisher Scientific) followed by blocking, primary antibody incubation, washing, HRP conjugated secondary antibody incubation, washing, and development as described above. Mouse monoclonal anti-β-actin (1:5000, ab6276; Abcam) was used as the primary antibody.

Statistical analysis {#s4-14}
--------------------

Differences in CNV volumes and mean level of protein or mRNA were compared using the Student t test or Mann--Whitney U test with Bonferroni correction for multiple comparisons. Differences in CNV occurrence in transgenic mice were compared with the χ^2^ test. Statistical significant was set at p\<0.05. Data are presented as mean ± SEM.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://www.elifesciences.org/the-journal/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for choosing to send your work entitled 'Photoreceptor Avascular Privilege is shielded by soluble VEGF receptor-1' for consideration at *eLife*. Your article has been evaluated by a Senior editor and 3 reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing Editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing Editor has assembled the following comments based on the reviewers\' reports.

Luo et al. present a series of experiments that suggest that soluble VEGFR1 (*sFlt-1*) is responsible for the avascularity of the photoreceptors and subretinal space. This group had previously published a study that linked *sFlt-1* expression in the cornea to the avascularity of the cornea. In order to test the normal function of *sFlt-1* the authors have blocked *sFlt-1* via three different, independent approaches: anti-sFLT-1 antibody, *sflt-1* conditional knockouts, and *sflt*-siRNA. Each one of the three approaches has its weaknesses, but the fact that each approach has the same outcome makes the overall study quite compelling. The model created by eliminating *sFlt-1* is of general interest since a simple KO of RPE *sFlt-1* yields a reproducible choroidal neovascular (CNV) response, i.e., a model for wet AMD without surgical intervention. Even more interesting is the observation that conditional KO of *sFlt-1* in RPE causes CNV whereas a conditional KO of *sFlt-1* in photoreceptors yields retinal angiomatous proliferation (RAP). The authors suggest that reduced levels of *sFlt-1* in the retina may be linked to diseases where blood vessels invade the photoreceptor layer, such as AMD.

The consensus of the reviewers is that this is an important study with significant clinical implications, but in its present form the manuscript has a number of issues, both experimentally and in terms of the level of detail in the writing. Both need to be addressed before it is suitable for publication.

1\) First, we would like to make a philosophical point. The authors should ensure that their central claim rests on experiments that are objectively reproducible or falsifiable. This field has been beset by data that do not meet that bar. For example, if other scientists fail to reproduce the subretinal injection experiments in which the outcome is CNV volume (e.g., [Figures 3B and D](#fig3){ref-type="fig"}), the authors could claim that special skill is required to do the micro-injection correctly. Therefore, the reviewers put more weight on experiments that require no special manipulation, in particular the RPE-specific and photoreceptor-specific *Flt-1* KOs. Other scientists should be able to breed these lines of mice, perform the histology, and see the neovascularization. If other scientists do not obtain the same result, then that would falsify the central claim of this paper. For this reason, the authors should present a quantification of the neovascularization events per retina for this particular set of experiments. Examples are shown in [Figure 4D](#fig4){ref-type="fig"} but one cannot tell whether this represents a common or rare occurrence in these eyes.

2\) Regarding RPE vs photoreceptor *sFlt-1* loss, it is hard to believe that loss of *sFlt-1* from one cell type would not be compensated for by diffusion of sFLT-1 made by the other cell type.

3\) It is not clear how exactly CNVs were quantified. We have the impression OCT was used as the main readout for CNV, which is questionable. Or was fluorescein or ICG data included in the quantification? If yes, how was this done? And how exactly was the OCT data quantified? Looking at the OCTs in [Figure 1B](#fig1){ref-type="fig"}, we would struggle to quantify changes here. Most importantly, how can CNVs be distinguished in this image modality from fluid build-up due to leakage? Why have the authors not used IHC to visualize the CNVs in whole mounts? This would make the CNV quantification data much more reliable. A similar criticism applies to [Figure 3C](#fig3){ref-type="fig"}. Why have the authors not used a vessel specific stain to show CNVs? It is impossible to be certain that vascular changes have occurred based on the H&E stains shown. The 'V' in CNV stands for 'vascularization', yet the authors do not show any vascular specific stains (apart from [Figure 4D](#fig4){ref-type="fig"}). This is a major weakness.

4\) [Figure 2](#fig2){ref-type="fig"}: the authors should more carefully characterize how *sFlt-1*, the blocking antibody, VEGF, and the anti VEGF antibodies may affect their VEGF and PlGF quantification. For instance, 'free VEGF' is mentioned. How can the authors be sure that their ELISA does not measure 'non-free' VEGF (bound to *sFlt-1*)? The authors seem to imply that the *sFlt-1* blocking antibody can displace VEGF from bound *sFlt-1* (thereby raising VEGF levels). This is a bit surprising, considering the very high affinity *sFlt-1* has for VEGF. The authors should demonstrate that this is possible for VEGF (but not for PlGF) in vitro.

5\) [Figure 2](#fig2){ref-type="fig"}: how can the authors explain the fact that PlGF is not changed? Similar questions as above arise. Is the anti-*sFlt-1* blocking antibody not capable of displacing PlGF (but it can do that with VEGF)? Also, can the authors be sure that they are measuring true 'free PlGF' (and not PlGF bound to *sFlt-1*)?

6\) [Figure 3A](#fig3){ref-type="fig"}: the authors claim their shRNA approach does not affect *mFlt-1*. Why have they not shown this in the Western blot in panel A (e.g., instead of β-actin)? This would be much more convincing.

7\) [Figure 3A](#fig3){ref-type="fig"}: why does the *sFlt-1* IHC look so completely different in [Figure 3A](#fig3){ref-type="fig"} compared to [Figure 1C](#fig1){ref-type="fig"}? In [Figure 3A](#fig3){ref-type="fig"} the RPE has similar intensity to the IS, whereas in [Figure 1C](#fig1){ref-type="fig"} the RPE is much weaker.

8\) [Figure 3A](#fig3){ref-type="fig"}: how far towards the inner retina is *sFlt-1* reduced? The authors show in [Figure 3A](#fig3){ref-type="fig"} only a very small part of the retina that does not include the IN, ON, and RGC layer. However, [Figure 1C](#fig1){ref-type="fig"} suggests that there is significant expression in these locations. Have these locations been affected?

9\) [Figure 3D](#fig3){ref-type="fig"}: the authors show in [Figure 1C](#fig1){ref-type="fig"} VEGF IHC in sections. This stain should be used to demonstrate where the VEGF protein is reduced.

10\) [Figure 4](#fig4){ref-type="fig"}: how quickly do the CNVs develop in the transgenic models? In both transgenic strains (*Vmd*~*2*~*-Cre* and *iCre-75*) the 'target tissues' (i.e., the RPE and photoreceptors) seems to be profoundly affected. We can't be certain there is not a primary effect (because in these experiments *sFlt-1* and *mFlt-1* are absent). A temporal study showing early vascular changes in the absence of changes in the transgenic target tissues could exclude this.

11\) One recurring piece of data is that CNV occurs in the control eyes, although at a lower incidence. It is never addressed why this happens. This should be discussed.

12\) For patient samples studied in [Figure 1](#fig1){ref-type="fig"}, please present a table summarizing each patient's age and clinical characteristics.

13\) A critical control experiment for recombination efficiency and location is needed for the subretinal injection of Cre plasmid, and the authors have the components for this experiment so it should not be difficult to perform. Indeed, they performed this control for the RPE and photoreceptor-specific lines. The experiment is to inject mTmG mice with subretinal Cre plasmid and see where and at what efficiency Cre-mediated recombination takes place. It would be nice to see this both in cross-section and in flatmounts of isolated retinas and eye-cups with the retina removed (to see the RPE en face). Subretinal injection of DNA has not been previously reported to produce particularly high efficiencies of DNA uptake. In this regard, we wonder why the authors did not use subretinal injection of AAV-cre, a mode of gene delivery that gives high efficiency transduction into RPE cells.
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Author response

*1) First, we would like to make a philosophical point. The authors should ensure that their central claim rests on experiments that are objectively reproducible or falsifiable. This field has been beset by data that do not meet that bar. For example, if other scientists fail to reproduce the subretinal injection experiments in which the outcome is CNV volume (e.g., [Figures 3B and D](#fig3){ref-type="fig"}), the authors could claim that special skill is required to do the micro-injection correctly. Therefore, the reviewers put more weight on experiments that require no special manipulation, in particular the RPE-specific and photoreceptor-specific* Flt-1 *KOs. Other scientists should be able to breed these lines of mice, perform the histology, and see the neovascularization. If other scientists do not obtain the same result, then that would falsify the central claim of this paper. For this reason, the authors should present a quantification of the neovascularization events per retina for this particular set of experiments. Examples are shown in [Figure 4D](#fig4){ref-type="fig"} but one cannot tell whether this represents a common or rare occurrence in these eyes*.

We appreciate the reviewers' constructive suggestions. In order to put more weight on experiments that require no special microsurgical manipulation, we have added more information in the revised manuscript and included a quantification of neovascular events as follows (indicated with italics at the end): "At 1-3 months of age, nearly all homozygous RPE-specific *Flt-1* knockout mice (*Vmd*~*2*~*-cre*^*+*^*flt-1*^*lox/lox*^) (18/22 eyes, 82%, *P=*1.3E-6), and about half of the heterozygous conditional *Flt-1* knockout mice (*Vmd*~*2*~*-cre*^+^ *flt-1*^*lox/+*^) (17/42 eyes, 40%, *P=*0.009) developed CNV, which progressed over time, compared with 18% (2/22 eyes, 9%) of littermate controls (*Vmd*~*2*~*-cre*^*+*^*flt-1*^*+/+*^). Similarly, at 1-3 months of age, both homozygous (*iCre-75*^*+*^*flt-1*^*lox/lox*^*,* 8/14 eyes, 57%, *P\<*0.05) and heterozygous (13/24 eyes, 54%, *P\<*0.05) photoreceptor-specific *Flt-1* knockout mice (*iCre-75*^*+*^*flt-1*^*lox/+*^) developed RAP, compared with 10% (1/10 eyes) of littermate controls *(iCre-75*^*+*^*flt-1*^*+/+*^). *FA was performed starting from P21 and we found that neovascular lesions could be detected as early as P28. In CNV or RAP eyes, the lesions appeared in variable numbers and sizes. A typical lesion is shown in [Figure 4D](#fig4){ref-type="fig"}, and the numbers of leakages in each eye range from 1-4 per eye. Some lesions appeared as scattered little spots ([Figure 4--figure supplement 3](#fig4s3){ref-type="fig"}).*

Furthermore, the other comments on the knockout experiments were addressed in the appropriate context in the revised manuscript.

*2) Regarding RPE vs photoreceptor* sFlt-1 *loss, it is hard to believe that loss of* sFlt-1 *from one cell type would not be compensated for by diffusion of sFLT-1 made by the other cell type*.

While diffusion of sFLT-1 between the RPE and photoreceptors is theoretically possible, the intervening inter photoreceptor matrix could trap sFLT-1, preventing free diffusion. In addition, sFLT-1 secretion by the RPE is polarized basally towards the choroid ([Figure 1C,D](#fig1){ref-type="fig"}). Therefore, excessive VEGF secretion from the RPE may overcome the normal anti-angiogenic balance if sFLT-1 is reduced, eliciting choroidal neovascularization. We have added the above to the revised manuscript.

*3) It is not clear how exactly CNVs were quantified. We have the impression OCT was used as the main readout for CNV, which is questionable. Or was fluorescein or ICG data included in the quantification? If yes, how was this done? And how exactly was the OCT data quantified? Looking at the OCTs in [Figure 1B](#fig1){ref-type="fig"}, we would struggle to quantify changes here. Most importantly, how can CNVs be distinguished in this image modality from fluid build-up due to leakage? Why have the authors not used IHC to visualize the CNVs in whole mounts? This would make the CNV quantification data much more reliable. A similar criticism applies to [Figure 3C](#fig3){ref-type="fig"}. Why have the authors not used a vessel specific stain to show CNVs? It is impossible to be certain that vascular changes have occurred based on the H&E stains shown. The "V" in CNV stands for "vascularization", yet the authors do not show any vascular specific stains (apart from [Figure 4D](#fig4){ref-type="fig"}). This is a major weakness*.

We apologize for not presenting sufficient information. We measured the CNV volumes in vivo by using optical coherence tomography (OCT) images according to established procedure (Schmucker Schaeffel, 2004; Joeres and Tsong et al., 2007; Furino and Ferrara et al., 2009; Ruggeri and Tsechpenakis et al., 2009; Giani and Thanos et al., 2011; Luo and Zhang et al., 2013). This method has been widely used for estimating CNV volumes in vivo, especially in AMD patients and has proved to provide highly reproducible quantitative measurements (Joeres and Tsong et al., 2007; Giani and Thanos et al., 2011; Luo and Zhang et al., 2013). In vivo measurements offer the advantage of following a single animal over time, which cannot be achieved by destructive histologic techniques. We added the above references to the revised manuscript. We compared this method to IHC staining on flatmounts and found good correlation (*r*=0.79, n=19, p=0.0006, data were not shown in this manuscript).

[Figure 1B](#fig1){ref-type="fig"} is a histological image of RAP from a human sample, not CNV. We quantified all CNV volumes but not RAP volumes in the experiment. It is hard to confirm the three-dimensional boundary of CNV from FA or ICG leakage but this can readily be done in a stack of OCT slices in vivo.

With respect to vascular staining, we now show in [Figure 3--figure supplement 4](#fig3s4){ref-type="fig"} that the lesions do contain CNV by isolectin staining. This is additionally corroborated by TEM ([Figure 3--figure supplement 4](#fig3s4){ref-type="fig"}).

*4) [Figure 2](#fig2){ref-type="fig"}: the authors should more carefully characterize how* sFlt-1*, the blocking antibody, VEGF, and the anti VEGF antibodies may affect their VEGF and PlGF quantification. For instance, "free VEGF" is mentioned. How can the authors be sure that their ELISA does not measure "non-free" VEGF (bound to* sFlt-1*)? The authors seem to imply that the* sFlt-1 *blocking antibody can displace VEGF from bound* sFlt-1 *(thereby raising VEGF levels). This is a bit surprising, considering the very high affinity* sFlt-1 *has for VEGF. The authors should demonstrate that this is possible for VEGF (but not for PlGF) in vitro*.

*5) [Figure 2](#fig2){ref-type="fig"}: how can the authors explain the fact that PlGF is not changed? Similar questions as above arise. Is the anti-*sFlt-1 *blocking antibody not capable of displacing PlGF (but it can do that with VEGF)? Also, can the authors be sure that they are measuring true "free PlGF" (and not PlGF bound to* sFlt-1*)*?

We performed a series of experiments to address the above two comments. First, we determined whether the neutralizing anti-FLT-l antibody affected the measurement of mouse VEGF-A and PlGF-2 (mice only have PlGF-2, not 1 and 3) by ELISA ([Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}). We did not find any significant difference.

Next, to determine whether our ELISA would detect VEGF-A that is bound to FLT-1, we examined the effect of excess recombinant FLT-1 protein on detection of VEGF-A and PlGF-2 by ELISA ([Figure 2--figure supplement 2](#fig2s2){ref-type="fig"}). In this assay, almost all VEGF-A (62.5pg/ml) would be expected to bind FLT-1 (100 ng/ml) based on an assumed Kd=10pM (Free VEGF-A can be estimated to be 1.36pg/ml by Michaelis-Menten kinetics). As shown in [Figure 2--figure supplement 2](#fig2s2){ref-type="fig"}, the ELISA showed less detection of VEGF-A and PLGS after saturation with excess recombinant FLT-1: i.e., it did not detect non-free VEGF-A and non-free PlGF-2. *These data demonstrate that non-free VEGF or non-free PLGF-2 is not being detected at significant levels by our ELISA technique.*

Finally, we determined whether anti-FLT-1 neutralizing antibody released VEGF-A but not PlGF-2 from recombinant FLT-1 ([Figure 2--figure supplement 3](#fig2s3){ref-type="fig"}). After coating ELISA plates with FLT-1 and then incubating with VEGF-A, FLT-1 neutralizing antibody was added with VEGF-A. The binding of VEGF-A to the recombinant FLT-1 was evaluated in the presence and in the absence of anti-FLT-1 antibody. Isotype IgG was used as a control. The same assay was performed with PlGF-2. *The results indicated that FLT-1 neutralizing antibody released VEGF-A but not PlGF-2 from recombinant FLT-1*. Although the exact reason for this is unknown, it is possible that FLT-1 neutralizing antibody may change the FLT-1 conformation, affecting binding of FLT-1 to VEGF-A but not PlGF-2.

We have added the above to the revised manuscript. Furthermore, it should be noted that there is little biologic relevance of effects on PlGF. [Figure 2E](#fig2){ref-type="fig"} shows that the PlGF level (0.8 pg/µg of protein extract with a very high error bar) is very low compared to that of VEGF (7 pg/µg of protein extract). Further, over-expression of PlGF induce by AAV injected into subretinal space does not alter at all the CNV volume (Tarallo and Bogdanovich et al., 2012).

*6) [Figure 3A](#fig3){ref-type="fig"}: the authors claim their shRNA approach does not affect* mFlt-1*. Why have they not shown this in the Western blot in panel A (e.g., instead of β-actin)? This would be much more convincing*.

We performed an experiment to demonstrate that AAV.shRNA.*sFlt-1* specifically affects sFLT-1 but not mFLT-1 by Western blot (see [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}); this has been included in the Results in the revised manuscript. Furthermore, the specificity of the shRNA used in this construct was demonstrated previously (Ambati and Nozaki et al., 2006).

*7) [Figure 3A](#fig3){ref-type="fig"}: why does the* sFlt-1 *IHC look so completely different in [Figure 3A](#fig3){ref-type="fig"} compared to [Figure 1C](#fig1){ref-type="fig"}? In [Figure 3A](#fig3){ref-type="fig"} the RPE has similar intensity to the IS, whereas in [Figure 1C](#fig1){ref-type="fig"} the RPE is much weaker*.

We did observe that the sFLT-1 IHC signal became stronger after subretinal injection with treatment or control ([Figure 3A](#fig3){ref-type="fig"}) eyes compared to normal eyes without injury ([Figure 1C](#fig1){ref-type="fig"}). The higher sFLT-1 expression might be due to the inflammatory reaction from injury. We have added the above to the revised manuscript.

*8) [Figure 3A](#fig3){ref-type="fig"}: how far towards the inner retina is* sFlt-1 *reduced? The authors show in [Figure 3A](#fig3){ref-type="fig"} only a very small part of the retina that does not include the IN, ON, and RGC layer. However, [Figure 1C](#fig1){ref-type="fig"} suggests that there is significant expression in these locations. Have these locations been affected*?

We observed no changes of sFLT-1 expression in inner retina in the two conditional *Flt*-*1*knockouts. However, sFLT-1 decreased somewhat in the inner retina following subretinal injection withAAV.shRNA.*sFlt-1*. This may be due to the diffusion and leakage of injection along the injection track. We have added the above to the revised manuscript.

*9) [Figure 3D](#fig3){ref-type="fig"}: the authors show in [Figure 1C](#fig1){ref-type="fig"} VEGF IHC in sections. This stain should be used to demonstrate where the VEGF protein is reduced*.

[Figure 1C](#fig1){ref-type="fig"} shows the distribution of sFLT-1 and VEGF in normal whole retina, and the distribution of the ratio of sFLT-1/VEGF ([Figure 1C](#fig1){ref-type="fig"}). A "theoretical" implication is that VEGF is prominent in the inner vascularized retina, the layer with blood vessels and neurons, while *sFlt-1* is prominent in the outer avascular retina. In order to show that the VEGF protein is indeed decreased by subretinal delivery of Cre into *Vegfa*^*loxp/loxp*^ mice, we injected pCre (+10% NeuroPORTER) into the subretinal space of *Vegfa*^*loxp/loxp*^ mice. The results (see [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}) show selective reduction of VEGF protein in the RPE cells. We added this result in the appropriate context within the revised manuscript. Western blot results confirmed Cre expression as well ([Figure 3--figure supplement 5](#fig3s5){ref-type="fig"}).

*10) [Figure 4](#fig4){ref-type="fig"}: how quickly do the CNVs develop in the transgenic models? In both transgenic strains (*Vmd~2~-Cre *and* iCre-75*) the "target tissues" (i.e., the RPE and photoreceptors) seems to be profoundly affected. We can't be certain there is not a primary effect (because in these experiments* sFlt-1 *and* mFlt-1 *are absent). A temporal study showing early vascular changes in the absence of changes in the transgenic target tissues could exclude this*.

The reviewers raise a good point: pathological disturbances in RPE or photoreceptors due to *Flt-1* knockout may themselves contribute to the development of CNV. It should be noted that there are several inherited retinal degeneration models with changes in RPE/photoreceptors where CNV does not develop -- therefore it is not a foregone conclusion that any pathological disturbances in these cells necessarily induces CNV. In the data previously presented, we found that the retina and RPE were normal in places where there was no CNV; however, CNV by its nature is anatomically disruptive to the RPE, which in turn leads to photoreceptor disruption. As *Flt-1* knockdown involves decreased *mFlt-1* as well, it is possible that genomic knockout could induce early profound retinal changes which secondarily induces CNV or RAP.

Hence, as recommended, we conducted a temporal study. We performed immunohistochemistry on sections of VMD-*Creflt*^*loxp/loxp*^ mice at p7, p14, and p21. There were no CNV lesions seen on retinal sections at these time points. However, we found evidence of nascent choroidal endothelial changes abutting Bruch's membrane at P21 ([Figure 4--figure supplement 7](#fig4s7){ref-type="fig"}). At p21, the earliest feasible time point for angiography (due to time of weaning), fluorescein angiography detected no CNV ([Figure 4--figure supplement 8](#fig4s8){ref-type="fig"}).The earliest time point that we detected CNV angiographically was at P28, when the overlying neural retina appears intact ([Figure 4--figure supplement 9](#fig4s9){ref-type="fig"}). Taken together, these data present early choroidal vascular changes without changes in the overlying neural retinal changes.

*11) One recurring piece of data is that CNV occurs in the control eyes, although at a lower incidence. It is never addressed why this happens. This should be discussed*.

Rare CNV occurrences did occur in the littermate controls ([Tables 2 and 3](#tbl2 tbl3){ref-type="table"}). These results may be due to Cre "leakiness" or toxicity which has been reported in several transgenic models using the Cre-lox system ([@bib14]; [@bib50]).

*12) For patient samples studied in [Figure 1](#fig1){ref-type="fig"}, please present a table summarizing each patient's age and clinical characteristics*.

The demographic characteristics of the patient samples are shown in [Table 1](#tbl1){ref-type="table"} in the revised manuscript.

*13) A critical control experiment for recombination efficiency and location is needed for the subretinal injection of Cre plasmid, and the authors have the components for this experiment so it should not be difficult to perform. Indeed, they performed this control for the RPE and photoreceptor-specific lines. The experiment is to inject mTmG mice with subretinal Cre plasmid and see where and at what efficiency Cre-mediated recombination takes place. It would be nice to see this both in cross-section and in flatmounts of isolated retinas and eye-cups with the retina removed (to see the RPE en face). Subretinal injection of DNA has not been previously reported to produce particularly high efficiencies of DNA uptake. In this regard, we wonder why the authors did not use subretinal injection of AAV-cre, a mode of gene delivery that gives high efficiency transduction into RPE cells*.

The use of 10% NeuroPORTER Transfection Reagent (Genlantis, San Diego, CA, USA) as a plasmid transfection enhancer has been reported to achieve high DNA uptake in the RPE (Kachi and Oshima et al., 2005). In addition, we have previously published on the successful use of this technique (Kaneko et al. Nature 2011; Tarallo et al. Cell 2012). The experiment for comment \#9 demonstrated the efficacy of this approach.
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[^1]: Department of Pathology, University of California, San Diego, La Jolla, United States.

[^2]: All humans are Caucasians.

[^3]: AMD: age-related macular degeneration; CNV: choroidal neovascularization; F: female; M: male; RAP: retinal angiomatous proliferation.
